The aim of this study was to increase the solubility and dissolution of Repaglinide and metformin hydrochloride -a practically water insoluble drug. To achieve complete drug release, various batches of solid dispersion of combination of Repaglinide and Metformin hydrochloride using water soluble carriers such as PEG (PEG 4000 as X1 and PEG 6000 as X2), were prepared as per the design expert (8.0.5) to optimize the drug release profile using response surface methodology (Face Centered central composite design). DSC and FTIR were used to characterize the solid dispersions. No chemical interaction was found between Repaglinide and Metformin hydrochloride and polymers. The solid dispersion prepared in this study was found to have higher dissolution rate and solubility compared to plain drug and physical mixture of drug and carriers. F8 was found to be optimized batch according to the Face Centered Central Composite Design (FCCCD). The tablet's hardness, thickness, drug content, weight fluctuation, friability, disintegration duration, and in vitro dissolution tests were tested after it was made using the optimised batch of SD.

Repaglinide, Metformin hydrochloride, Face Centered Central Composite Design, PEG, Solid dispersion, Tablet, etc.